arrow_back Back to App

Accelerating Addiction Vaccine Development and $1 Billion Prize

This bill aims to speed up the development of vaccines for opioid, cocaine, methamphetamine, and alcohol use disorders. It introduces special facilitations for the approval process of such vaccines and offers a one-billion-dollar prize to the first company that develops and mass-produces an effective vaccine. This initiative seeks to combat the addiction crisis by providing new tools for prevention and treatment.
Key points
Faster Approval: Addiction vaccines will be designated as "breakthrough therapies" and "fast track products," accelerating their market entry.
Priority Review: Applications for these vaccines will receive priority review by regulatory bodies.
Financial Incentive: The first company to develop and mass-produce an approved addiction vaccine will receive a $1 billion prize.
Time Limit: The approval facilitations will be effective for 10 years from the enactment date of the bill.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7827
Sponsor: Rep. Schweikert, David [R-AZ-1]
Process start date: 2024-03-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7827.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-26.

What are the main provisions?

Key points include:

  • Faster Approval: Addiction vaccines will be designated as "breakthrough therapies" and "fast track products," accelerating their market entry.
  • Priority Review: Applications for these vaccines will receive priority review by regulatory bodies.
  • Financial Incentive: The first company to develop and mass-produce an approved addiction vaccine will receive a $1 billion prize.
  • Time Limit: The approval facilitations will be effective for 10 years from the enactment date of the bill.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health